NMN and NR for Women: VA Coverage, Costs, and How to Pay Less

What Are NMN and NR, and Why Are Women Interested?

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors to NAD+, a coenzyme that sits at the center of cellular energy production and DNA repair. Both compounds raise circulating NAD+ levels in humans, a fact confirmed in several small trials including a 2020 randomized crossover study in Nature Metabolism showing that 300 mg of NR daily raised whole-blood NAD+ by approximately 40 to 50 percent over eight weeks in healthy middle-aged adults.

Interest among women specifically has grown for three reasons. First, NAD+ levels decline with age in both sexes, but women face a compounding drop during perimenopause and menopause as estrogen, which supports NAD+ biosynthesis through the tryptophan-kynurenine pathway, falls sharply. Second, conditions disproportionately affecting women, including PCOS-associated insulin resistance, postpartum metabolic changes, and the accelerated cardiovascular aging that follows menopause, all involve mitochondrial function where NAD+ plays a direct role. Third, early animal data on NAD+ and ovarian aging generated significant lay-media coverage, pulling women into the conversation years before human fertility data existed.

The honest answer on evidence: most human trials to date have been small, short, and not stratified by sex or hormonal status. A 2023 systematic review in Ageing Research Reviews covering 14 human NMN and NR trials found no trial was powered to detect sex-specific outcomes. Women have been under-represented. What is extrapolated from animal or mixed-sex data versus directly studied in women will be called out throughout this article.

How NMN Differs From NR

NMN has a larger molecular structure than NR and must be converted to NR before entering most cells. Some researchers argue this makes NR the more bioavailable option at equivalent doses, though head-to-head human pharmacokinetic data comparing the two directly in women is not yet published. Both compounds are sold as dietary supplements in the U.S. And are regulated under DSHEA, not as drugs, meaning no prescription is required and no FDA pre-market approval of safety or efficacy has occurred.

The Life-Stage Picture

• Reproductive years. No evidence supports use for cycle regulation or fertility. Animal studies on oocyte quality exist but do not translate directly to human dosing or outcomes.
• Trying to conceive or pregnant. See the dedicated pregnancy section below. Short version: avoid.
• Perimenopause. The most plausible target population based on the biology of estrogen-NAD+ interaction. No dedicated perimenopause RCT has been published as of early 2026.
• Post-menopause. The CALERIE-adjacent pilot work on NAD+ and cardiometabolic markers included post-menopausal women and found modest improvements in insulin sensitivity over 12 weeks at 1,000 mg NMN daily, but the sample was 25 participants.

Does the VA Cover NMN or NR?

The VA does not cover NMN or NR. This is a firm, current position, not a gray area.

The VA National Formulary covers FDA-approved prescription drugs. NMN and NR are classified as dietary supplements under the Dietary Supplement Health and Education Act of 1994. The VA Pharmacy Benefits Management Services explicitly limits formulary coverage to FDA-approved drug products and does not reimburse dietary supplements through TRICARE pharmacy benefits or the VA's community care network.

What the VA Does Cover That May Be Relevant

If you are a woman veteran and your underlying concern is metabolic health, fatigue, or cardiovascular risk after menopause, the VA formulary does cover several evidence-based treatments that address similar downstream goals:

• Metformin for insulin resistance or type 2 diabetes prevention (covered, generic, low cost)
• Hormone therapy for menopausal symptoms, where clinically appropriate (covered for many veterans)
• Thiamine and B-vitamin supplementation for documented deficiency (covered when medically indicated)
• Statin therapy for cardiovascular risk reduction (fully covered on formulary)

None of these replaces NMN or NR, but for women veterans whose primary goal is metabolic or cardiovascular protection after menopause, a VA primary care conversation about evidence-based formulary options is worth having before spending out-of-pocket on supplements with thinner evidence.

TRICARE and Supplements

TRICARE, which covers active duty and some reservist populations, similarly does not reimburse dietary supplements. TRICARE's benefit exclusion list specifically excludes vitamins, minerals, and nutritional supplements unless they are used as part of a covered medical treatment and prescribed by an authorized provider in that context. NMN and NR do not currently meet that threshold.

Does Commercial Insurance or Medicare Cover NMN or NR?

No commercial insurance plan or Medicare Part D plan covers NMN or NR as of 2026.

Because both compounds are dietary supplements, they fall outside the definition of a "covered drug" under Part D. Medicare Part D covers only drugs approved by the FDA under an NDA or ANDA and listed on a plan's formulary. Supplement manufacturers have lobbied for reclassification, but no regulatory change has occurred.

Medicaid similarly does not cover dietary supplements except in narrow medically necessary circumstances (such as enteral nutrition formulas), and NMN or NR would not qualify.

Real Ways to Reduce Your Cost

Cash pay is the only path right now. Here is what actually moves the number.

Subscription and Auto-Ship Discounts

Most branded NMN and NR companies offer 15 to 30 percent off retail when you enroll in auto-ship. At an average retail price of $80 per month, a 20 percent subscription discount brings the monthly cost to $64. Compare the per-gram price across brands, not the per-capsule price, because dose per capsule varies widely (125 mg to 500 mg per capsule is the common range).

HSA and FSA: Possible but Not Automatic

Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) are governed by IRS rules under IRS Publication 502, which specifies that supplements are eligible only when purchased to treat a specific diagnosed medical condition on the advice of a physician. A Letter of Medical Necessity (LMN) written by your doctor stating that NMN or NR is recommended to treat a named diagnosis may allow HSA or FSA reimbursement, but plan administrators have discretion. This is worth asking your HSA administrator about directly before assuming eligibility.

Telehealth Prescriptions and Compounding

Some telehealth platforms prescribe compounded NMN through 503A compounding pharmacies. Compounded NMN is not the same as commercially manufactured NMN: it is mixed at a pharmacy to a specified dose and is not FDA-reviewed for the compounded formulation. Pricing varies but has been advertised in the $40 to $70 per month range for compounded NMN capsules.

A practical framework for women evaluating the compounded vs. Branded NMN decision:

| Factor | Branded Supplement | Compounded NMN | |---|---|---| | FDA oversight | None (DSHEA) | None for the compounded product itself | | Third-party testing | Varies; look for NSF or USP certification | Varies by pharmacy; ask for COA | | Requires clinician | No | Yes (prescription required) | | Average monthly cost | $60-$90 | $40-$70 | | Insurance coverage | None | None | | Dose flexibility | Fixed by manufacturer | Customizable |

If you pursue compounding, ask the pharmacy for a certificate of analysis (COA) confirming purity and potency. The FDA has issued guidance noting that compounding pharmacies must meet specific standards, and 503A pharmacy oversight varies by state.

Buying in Bulk and Price-Per-Gram Math

A 60-day supply typically costs less per gram than a 30-day supply from the same brand. At $80 for 30 days at 500 mg/day, you are paying $0.27 per 100 mg. Brands selling 120-capsule bottles of 500 mg NMN at $120 bring that to $0.10 per 100 mg. Do the math before defaulting to the smallest available size.

Clinical Trials

If you are a woman between 40 and 65 with metabolic or menopausal concerns and you want access to NMN or NR at no cost, check ClinicalTrials.gov for enrolling studies. Several academic centers are currently running or recruiting for NAD+ precursor trials in perimenopausal and post-menopausal women. Participation provides the supplement free, often with monitoring and bloodwork included.

Pregnancy, Lactation, and Contraception

Do not use NMN or NR during pregnancy. There is no human safety data. Animal studies show NAD+ precursors are biologically active in embryonic development, which makes the absence of human data a reason for caution, not reassurance.

A 2018 study in Nature Medicine demonstrated that NMN supplementation in pregnant mice prevented certain congenital birth defects linked to NAD+ deficiency, which generated interest in potential human applications. Researchers were careful to note, however, that this was a mouse model of NAD deficiency, not a therapeutic recommendation for pregnant women, and that the pharmacology of supplemental NMN in human pregnancy is entirely unstudied.

Lactation: No data exist on NMN or NR transfer into human breast milk, on infant exposure, or on effects in a nursing infant. Because NAD+ metabolites are biologically active, the theoretical possibility of infant exposure cannot be dismissed. Avoidance during lactation is the prudent position.

Contraception: NMN and NR are not teratogens with a known mechanism in humans, so there is no regulatory mandate for contraception as there would be with isotretinoin or thalidomide. The practical recommendation is straightforward: if you are trying to conceive, pregnant, or breastfeeding, pause NMN or NR and discuss your NAD+ support goals with your OB-GYN or midwife. Dietary sources of niacin and tryptophan, which support endogenous NAD+ synthesis, carry no supplemental safety concerns in pregnancy at normal dietary amounts.

Who This Is and Is Not Right For

Women Who May Have a Reasonable Rationale for NMN or NR

• Post-menopausal women with metabolic concerns, fatigue, or interest in longevity who have already addressed evidence-based priorities (lifestyle, hormone therapy discussion, statin consideration if indicated) and want to add a supplement with early-phase human data and an acceptable safety profile for the healthy adult population.
• Perimenopausal women experiencing energy changes who understand they are using a supplement with plausible biology but no phase 3 trial data in their life stage.
• Women with PCOS and insulin resistance who are interested in mitochondrial support: the 2022 human trial by Yoshino et al. In Science found 1,000 mg/day of NMN over 10 weeks improved muscle insulin sensitivity in post-menopausal women with prediabetes, the most specific human efficacy data available in a female population to date.

Women for Whom This Is Likely Not Right

• Women who are pregnant or trying to conceive. Full stop.
• Women who are breastfeeding.
• Women under 35 with no metabolic or mitochondrial indication. The age-related NAD+ decline is modest before 40, and spending $80 per month on a supplement with thin evidence is hard to justify at that stage.
• Women whose primary budget for supplements would be better directed at vitamin D, omega-3s, or magnesium, all of which have stronger evidence bases and lower costs.
• Women taking medications that interact with NAD+ metabolism, including isoniazid (used for tuberculosis) or high-dose niacin therapy. Ask your pharmacist before combining.

Sex-Specific Pharmacology: What We Know and Don't

The pharmacokinetics of NMN and NR have not been formally studied with sex as a primary variable in any published trial. What follows is what can be cautiously inferred.

Estrogen and NAD+ Biosynthesis

Estrogen promotes expression of NAMPT, the rate-limiting enzyme in the salvage pathway that produces NAD+ from nicotinamide. As estrogen falls in perimenopause and post-menopause, NAMPT activity may decrease, which could make exogenous NAD+ precursor supplementation more biologically meaningful in older women than in premenopausal women. This is the mechanistic rationale cited by researchers like Sinclair et al. and others, but it has not been formally tested as a dose-response question in women at different hormonal stages.

Body Composition and Dosing

Women have, on average, a higher percentage of body fat and lower skeletal muscle mass than men of similar weight. Because much of NAD+ metabolism occurs in muscle tissue, the tissue distribution of NMN and NR may differ between the sexes. No published trial has reported sex-stratified pharmacokinetic data. This is a genuine evidence gap.

The Yoshino 2022 Trial in Detail

The Yoshino et al. Science 2021 trial enrolled 25 post-menopausal women with prediabetes or overweight and randomized them to 1,000 mg/day of NMN or placebo for 10 weeks. NMN increased skeletal muscle insulin sensitivity compared to placebo, as measured by hyperinsulinemic-euglycemic clamp. Whole-body glucose disposal improved. The trial did not show changes in body weight, fat mass, blood pressure, or lipids. This is the highest-quality female-specific efficacy datum available and should anchor any conversation about what NMN may and may not do for women metabolically.

What to Ask Your Provider Before Starting

If you are working with a WomanRx clinician or your own OB-GYN, endocrinologist, or NP, these questions will get you a more useful conversation than "should I take NMN?"

1. Given my current NAD+ precursor status (niacin intake, tryptophan intake), is supplementation likely to produce meaningful additional NAD+ elevation?
2. Are there evidence-based interventions for my specific concern (insulin resistance, fatigue, cardiovascular risk) that should come before or alongside a supplement?
3. Is there a clinical trial I could join that would give me access to NMN or NR with monitoring at no cost?
4. If I pursue compounding, which pharmacy do you trust for purity verification?
5. Does my HSA administrator accept a Letter of Medical Necessity for this supplement?